Sensyne Health announced Thursday, Oct. 10, that it has joined Bayer’s newest innovation hub, LifeHub UK, and will work toward developing solutions for automated image evaluation.
Bayer launched LifeHub UK to bring a variety of healthcare companies together for improving “disease detection and data-driven drug discovery” through the development of AI-enabled imaging technologies. Sensyne Health is one of the first companies to join LifeHub UK.
“Initiatives like this are essential to quickly maximize the opportunity AI presents to improve patient care and accelerate medical research,” Lord (Paul) Drayson, PhD, CEO of Sensyne Health, said in a prepared statement. “I’m delighted to be working with Bayer, extending our partnership to deliver the benefits of digital innovation directly to clinicians and patients.”
“We are delighted to launch LifeHub UK,” Kemal Malkin, a member of the Bayer Board of Management, said in the same statement. “We firmly believe that artificial intelligence has transformative potential for healthcare, leading to enhancements in prediction, prevention and personalized treatments.”
Michael has more than 16 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.